Live Breaking News & Updates on Nasdaq Immx|Page 5

Stay updated with breaking news from Nasdaq immx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 24.3% in March

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Rating) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 146,500 shares, a growth of 24.3% from the February 28th total of 117,900 shares. Based on an average trading volume of 182,200 shares, the […] ....

United States , Roth Mkm , Renaissance Technologies , Virtu Financial , Lynwood Capital Management Inc , Immix Biopharma Inc , Topco Ltd , Immix Biopharma , Get Rating , Montreal Can , Capital Management , Immix Biopharma Daily , Nasdaq Immx ,

Nexo Achieves Market Capitalization of $378.20 Million (NEXO)

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Rating) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 146,500 shares, a growth of 24.3% from the February 28th total of 117,900 shares. Based on an average trading volume of 182,200 shares, the short-interest ratio is […] ....

United States , Roth Mkm , Immix Biopharma Company Profile , Topco Ltd , Immix Biopharma Inc , Lynwood Capital Management Inc , Renaissance Technologies , Virtu Financial , Immix Biopharma , Get Rating , Montreal Can , Capital Management , Immix Biopharma Daily , Nasdaq Immx ,

ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of

Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma. ....

Ilya Rachman , Gabriel Morris , Immix Biopharma Inc , Drug Administration , Clinical Trial , Tissue Specific Therapeutics , Good Manufacturing Practice , Immix Biopharma , Nasdaq Immx , Immix Biopharma ,

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S.

One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA. ....

Ilya Rachman , Gabriel Morris , Immix Biopharma Inc , Johnson Company , Soft Tissue Sarcoma , Tissue Specific Therapeutics , Immix Biopharma , Rare Pediatric Disease Designation , Nasdaq Immx , Immix Biopharma ,